This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.
Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval
by Zacks Equity Research
Hologic's (HOLX) receipt of FDA approval for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system is likely to boost its Diagnostic segment.
Masimo (MASI) Launches Trace Data and Reporting Tool in US
by Zacks Equity Research
Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.
Genomic Health's Cost Pressure Mounts, Cancer Tests Strong
by Zacks Equity Research
Concerns related to Genomic Health's (GHDX) strong dependence on breast cancer tests still linger. Also, higher production cost and expenses continue to weigh heavily on the company's margins.
Integra Rides High on Product Launches, Competition Rife
by Zacks Equity Research
Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.
Henry Schein to Offer CAS' Fully-Automated Cognivue Device
by Zacks Equity Research
Henry Schein (HSIC) is consistently working toward boosting its Medical segment.
Hill-Rom (HRC) Rides on Product Launches, Competition Rife
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation through research and development. Its product launches slated for the fourth quarter are boosting investors' confidence.
Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line
by Zacks Equity Research
Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.
Boston Scientific's Apama Deal to Boost Electrophysiology Arm
by Zacks Equity Research
Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.
Capricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session
by Zacks Equity Research
Capricor Therapeutics (CAPR) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.
Quest Diagnostics Buys 2 Outreach Labs, Widens Customer Base
by Zacks Equity Research
Quest Diagnostics (DGX) completes acquisition of outreach laboratory services of two Hartford HealthCare hospitals. The deal is expected to widen the network of the company.
Abbott Gets FDA Nod for FreeStyle Libre, Boosts Diabetes Arm
by Zacks Equity Research
Abbott's (ABT) diabetes care segment to strengthen with the FDA approval for FreeStyle Libre Flash glucose monitoring system.
Edwards Lifesciences Pipeline Impressive, Currency Woes Stay
by Zacks Equity Research
Edwards Lifesciences (EW) rides high on product launches as well as strength in the global Transcatheter Aortic Valve Replacement market.
Quest Diagnostics to Buy Shiel to Widen Footprint in NY-NJ
by Zacks Equity Research
After the completion of Shiel's acquisition, the medical lab is expected to expand Quest Diagnostics' (DGX) physician and patient service centers network in the New York-New Jersey area.
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker Corporation (SYK) has successfully expanded its product portfolio over time, which aids the company to cater to evolving demands of customers.
Here's Why You Should Invest in Orthofix International Now
by Zacks Equity Research
Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.
New Strong Buy Stocks for September 22nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Quidel Corporation (QDEL) Jumps: Stock Rises 6.5%
by Zacks Equity Research
Quidel Corporation (QDEL) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.
Orthofix (OFIX) is a Great Momentum Pick for You: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, Orthofix (OFIX) stands out as one of the most suitable momentum stock.
Anika (ANIK) Grows in Orthopedic Medicines on Positive Data
by Zacks Equity Research
Anika Therapeutics' (ANIK) data shows HYALOFAST as an effective treatment option for cartilage lesions, suitable to all age groups.
Orthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2
by Zacks Equity Research
Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation businesses. Moreover, raised full-year 2017 guidance buoys optimism.
Zacks Industry Outlook Highlights: Varian Medical Systems, Inogen, Edwards Lifesciences, Orthofix International and INSYS Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Varian Medical Systems, Inogen, Edwards Lifesciences, Orthofix International and INSYS Therapeutics
MedTech Industry Outlook - July 2017
by Zacks Equity Research
The overall expectation is that President Trump's legislative change for MedTech will result in lower taxes and regulation for the industry as a whole.
MedTech Industry Outlook - March 2017
by Zacks Equity Research
A shrinking customer base indicates an impending slash in the demand for expensive medical procedures and devices.
Orthofix International (OFIX) Looks Good: Stock Jumps 9.9%
by Zacks Equity Research
Orthofix International N.V. (OFIX) moved big last session, as its shares jumped almost 10% on the day.